Literature DB >> 32126455

The role of substance use disorders in experiencing a repeat opioid overdose, and substance use treatment patterns among patients with a non-fatal opioid overdose.

Ruchir N Karmali1, G Thomas Ray2, Andrea L Rubinstein3, Stacy A Sterling4, Constance M Weisner5, Cynthia I Campbell6.   

Abstract

BACKGROUND: A non-fatal opioid overdose (NFOO) increases the risk of another overdose and identifies high-risk patients. We estimated the risk of repeat opioid overdose for patients with and without substance use disorder (SUD) diagnoses and the change in substance use treatment utilization rates associated with the first NFOO.
METHODS: We selected patients (>18 years of age) from Kaiser Permanente Northern California with a NFOO between 2009-2016 (n = 3,992). Cox proportional hazards models estimated the 1-year risk of opioid overdose associated with SUD diagnoses (opioid, alcohol, cannabis, amphetamine, sedative, and cocaine), controlling for patient characteristics. Among patients with an index NFOO, we calculated monthly utilization rates for outpatient substance use services and buprenorphine before and after the index overdose. Interrupted time series models estimated the change in level and trend in utilization rates associated with the index overdose.
RESULTS: Approximately 7.2 % of patients had a repeat opioid overdose during the year after the index NFOO. The only SUD diagnosis significantly associated with greater risk of repeat overdose was opioid use disorder (OUD) (aHR: 1.51; 95 % CI: 1.13-2.01). Before the index overdose, 4.16 % of patients received outpatient substance use services and 1.32 % received buprenorphine. The index overdose was associated with a 5.94 % (standard error: 0.77 %) absolute increase in outpatient substance use services and a 1.29 % (standard error: 0.15 %) increase in buprenorphine.
CONCLUSION: Patients with a NFOO and OUD are vulnerable to another overdose. Low initiation rates for substance use treatment after a NFOO indicate a need to address patient, provider, and system barriers.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Opioid overdose; Substance use disorder; Substance use treatment

Mesh:

Substances:

Year:  2020        PMID: 32126455      PMCID: PMC7238973          DOI: 10.1016/j.drugalcdep.2020.107923

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  39 in total

Review 1.  Managing Opioid Withdrawal in the Emergency Department With Buprenorphine.

Authors:  Andrew A Herring; Jeanmarie Perrone; Lewis S Nelson
Journal:  Ann Emerg Med       Date:  2019-01-05       Impact factor: 5.721

2.  Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration.

Authors:  Adam J Gordon; Greg Kavanagh; Margaret Krumm; Rajeev Ramgopal; Sanjay Paidisetty; Minu Aghevli; Francine Goodman; Jodie Trafton; Joseph Liberto
Journal:  Psychol Addict Behav       Date:  2011-06

3.  Attitudes Toward Naloxone Prescribing in Clinical Settings: A Qualitative Study of Patients Prescribed High Dose Opioids for Chronic Non-Cancer Pain.

Authors:  Shane R Mueller; Stephen Koester; Jason M Glanz; Edward M Gardner; Ingrid A Binswanger
Journal:  J Gen Intern Med       Date:  2016-10-31       Impact factor: 5.128

4.  Opioid Prescribing After Nonfatal Overdose and Association With Repeated Overdose: A Cohort Study.

Authors:  Marc R Larochelle; Jane M Liebschutz; Fang Zhang; Dennis Ross-Degnan; J Frank Wharam
Journal:  Ann Intern Med       Date:  2015-12-29       Impact factor: 25.391

5.  Changes in Outpatient Services and Medication Use Following a Non-fatal Opioid Overdose in the West Virginia Medicaid Program.

Authors:  Neel Koyawala; Rachel Landis; Colleen L Barry; Bradley D Stein; Brendan Saloner
Journal:  J Gen Intern Med       Date:  2019-06       Impact factor: 5.128

6.  Integration of screening, assessment, and treatment for cannabis and other drug use disorders in primary care: An evaluation in three pilot sites.

Authors:  Julie E Richards; Jennifer F Bobb; Amy K Lee; Gwen T Lapham; Emily C Williams; Joseph E Glass; Evette J Ludman; Carol Achtmeyer; Ryan M Caldeiro; Malia Oliver; Katharine A Bradley
Journal:  Drug Alcohol Depend       Date:  2019-06-08       Impact factor: 4.492

7.  Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.

Authors:  Jake R Morgan; Bruce R Schackman; Jared A Leff; Benjamin P Linas; Alexander Y Walley
Journal:  J Subst Abuse Treat       Date:  2017-07-03

Review 8.  Use of interrupted time series analysis in evaluating health care quality improvements.

Authors:  Robert B Penfold; Fang Zhang
Journal:  Acad Pediatr       Date:  2013 Nov-Dec       Impact factor: 3.107

9.  The HMO Research Network Virtual Data Warehouse: A Public Data Model to Support Collaboration.

Authors:  Tyler R Ross; Daniel Ng; Jeffrey S Brown; Roy Pardee; Mark C Hornbrook; Gene Hart; John F Steiner
Journal:  EGEMS (Wash DC)       Date:  2014-03-24

Review 10.  Methodologic limitations of prescription opioid safety research and recommendations for improving the evidence base.

Authors:  Shabbar I Ranapurwala; Rebecca B Naumann; Anna E Austin; Nabarun Dasgupta; Stephen W Marshall
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-06-03       Impact factor: 2.890

View more
  6 in total

1.  Opioid overdose survivors: Medications for opioid use disorder and risk of repeat overdose in Medicaid patients.

Authors:  Stephen Crystal; Molly Nowels; Hillary Samples; Mark Olfson; Arthur Robin Williams; Peter Treitler
Journal:  Drug Alcohol Depend       Date:  2022-01-10       Impact factor: 4.492

2.  Gaps in naloxone ownership among people who inject drugs during the fentanyl wave of the opioid overdose epidemic in New York City, 2018.

Authors:  Alexis V Rivera; Michelle L Nolan; Denise Paone; Sidney A Carrillo; Sarah L Braunstein
Journal:  Subst Abus       Date:  2022       Impact factor: 3.984

Review 3.  Assessing opioid overdose risk: a review of clinical prediction models utilizing patient-level data.

Authors:  Iraklis Erik Tseregounis; Stephen G Henry
Journal:  Transl Res       Date:  2021-03-21       Impact factor: 10.171

4.  Prevalence of Mental Health Disorders among Individuals Enrolled in an Emergency Response Program for Treatment of Opioid Use Disorder.

Authors:  Christine Bakos-Block; James R Langabeer; Andrea Yatsco; Marylou Cardenas-Turanzas; Tiffany Champagne-Langabeer
Journal:  Subst Abuse       Date:  2020-12-21

Review 5.  Mental disorder and opioid overdose: a systematic review.

Authors:  Jenna van Draanen; Christie Tsang; Sanjana Mitra; Vanessa Phuong; Arata Murakami; Mohammad Karamouzian; Lindsey Richardson
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2021-11-18       Impact factor: 4.519

6.  The opioid use disorder core outcomes set (OUD-COS) for treatment research: findings from a Delphi consensus study.

Authors:  Niranjan S Karnik; John Marsden; Connor McCluskey; Randy A Boley; Katharine A Bradley; Cynthia I Campbell; Megan E Curtis; David Fiellin; Udi Ghitza; Kathryn Hefner; Yih-Ing Hser; R Kathryn McHugh; Sterling M McPherson; Larissa J Mooney; Landhing M Moran; Sean M Murphy; Robert P Schwartz; Dikla Shmueli-Blumberg; Matisyahu Shulman; Kari A Stephens; Katherine E Watkins; Roger D Weiss; Li-Tzy Wu
Journal:  Addiction       Date:  2022-04-25       Impact factor: 7.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.